Accessibility Menu

Vogenx(NASDAQ) VOGX

Market Cap$219.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+21%
5 YearN/A
1 YearN/A
1 MonthN/A
$18.75
+19.05%
+3.00Today
Vogenx last closing stock price
MetricPriceDate
Last closeUSD 15.752026-08-17
Vogenx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
Since inception+21.15%USD 13.002026-08-12

Vogenx Financials at a Glance

Market Cap

$219.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$0.83

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$18.75

Volume

272,600.121

Open

$18.63

Previous Close

$15.75

Daily Range

$18.29 - $19.03

52-Week Range

$12.95 - $19.03

Estimated Earnings Date

N/A

VOGX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vogenx

Vogenx Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for serious metabolic diseases. The company focuses on conditions such as post-bariatric hypoglycemia and gastroparesis, with its lead product candidate being mizagliflozin.

Products and Services
  • Mizagliflozin: An oral drug candidate for treating PBH and gastroparesis
  • Research and development of novel therapeutics targeting metabolic dysfunctions
  • Potential treatments for GIP-dependent Cushing's Syndrome
Growth Outlook
  • Strong pipeline with a focus on unmet medical needs in metabolic disorders
  • Increasing demand for innovative treatments in the biopharmaceutical sector
  • Strategic partnerships may enhance research capabilities and market reach
Financial Highlights
  • Stock price range between 12.95 and 16.65 over the past year
  • Recent trading volume of 34,143 shares indicates active market interest
  • Market capitalization remains poised for growth as product development progresses
Vogenx Inc. operates in the biotechnology industry, emphasizing the discovery and development of therapeutics that address significant health challenges. The company's lead candidate, mizagliflozin, is positioned to meet the needs of patients suffering from metabolic disorders, which are often overlooked in the current healthcare landscape. With a robust growth outlook and a focus on innovative solutions, Vogenx Inc. is well-placed to capitalize on emerging opportunities in the biopharmaceutical market. The recent stock price performance and trading activity reflect investor interest, suggesting potential for future growth as the company advances its product pipeline.
AI Generated • Aug 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

James Green, MBA

Website

www.vogenx.com

Headquarters

Raleigh, NC 27609, US

VOGX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$219.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.91M

Volume

272.60K

Avg. Volume

166.85K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Vogenx Performance Analysis

Vogenx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Vogenx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.16N/A
20252025-12-31USD -0.10-34.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$219.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$0.48

N/A

EBITDA

-$0.46

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.09

N/A

Total Debt

$0.84

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.84

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$0.35

N/A

Operating Cash Flow

-$0.35

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,754.42-0.00%
^DJIDJI
$53,461.25-0.01%
^IXICNASDAQ
$26,653.02-0.00%
BTCBitcoin
$64,341.00+0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.91+0.14%
SLESuper League Enterprise
$5.42+0.79%
NOKNokia
$10.46-0.03%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$130.50-0.14%

Questions About VOGX

What is the current price of Vogenx?

Vogenx is trading at $18.80 per share.

What is the 52-week range for Vogenx?

Over the past 52 weeks, Vogenx has traded between $12.95 and $19.03.

How much debt does Vogenx have?

As of the most recent reporting period, Vogenx reported total debt of $835.80K.

How much cash does Vogenx have on hand?

Vogenx reported $250.75K in cash and cash equivalents in its most recent financial results.

What is Vogenx’s dividend yield?

Vogenx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services